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Hepatitis C virus (HCV) is a major causative agent of severe liver disease including ﬁbrosis, cirrhosis and
liver cancer. Therapy has improved over the years, but continues to be associated with adverse side
effects and variable success rates. Furthermore, a vaccine protecting against HCV infection remains
elusive. Development of more effective intervention measures has been delayed by the lack of a
suitable animal model. Naturally, HCV infects only humans and chimpanzees. The determinants of this
limited host range are poorly understood in part due to difﬁculties of studying HCV in cell culture. Some
progress has been made elucidating the barriers for the HCV lifecycle in non-permissive species which
will help in the future to construct animal models for HCV infection, immunity and pathogenesis.
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Hepatitis C virus (HCV) is a positive-sense, single stranded
RNA virus classiﬁed within hepacivirus genus of the Flaviviridae
family. HCV has a high propensity for establishing lifelong
persistent infections, which are associated with a signiﬁcant risk
of progressive liver ﬁbrosis and hepatocellular carcinoma. World-
wide at least 130 million people are chronically infected resultingll rights reserved.in an estimated 366,000 deaths due to cirrhosis and cancer
annually (Perz et al., 2006). Epidemiological data is incomplete
and in the United States alone the frequency of chronic carriers
may be twice as high (Edlin, 2011). Thus, HCV poses a major
public health threat. Treatment options have improved but are
still limited. Furthermore, the current standard of care, consisting
of a combination of pegylated interferon (IFN) alpha, the nucleo-
side analog, ribavirin (RBV), and one of two HCV NS3–4A protease
inhibitors, boceprevir or telaprevir, is not well tolerated. Prior to
the approval of these directly acting antivirals (DAAs) roughly 50%
of genotype 1 infected patients – clinically, the hardest HCV sub-
strain to treat – who underwent treatment, cleared the infection.
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has increased sustained virological response (SVR) rates in certain
clinical trial cohorts to 60–70% (Jacobson et al., 2011; Kwo et al.,
2010; McHutchison et al., 2009; Poordad et al., 2011). Currently,
numerous viral and host proteins are being pursued as antiviral
drug targets. Second-generation protease inhibitors and several
compounds interfering with the functions of the NS5A phospho-
protein and the RNA-dependent RNA polymerase, NS5B, are
already being tested in clinical trials (Yang et al., 2011). A
combination of orally administered DAAs with distinct mechan-
isms of action holds promise to boost SVR rates across all HCV
patient cohorts. Despite these successes unexpected toxicity in
late-stage clinical trials has led to the discontinuation or delays
in development of some very potent compounds, including
the protease inhibitor BILN2061 (Lamarre et al., 2003), the
nucleotide polymerase inhibitor BMS-986094(Vernachio et al.,
2011), and the cyclophilin A antagonist, alisporivir (Coelmont
et al., 2009). These challenges highlight the need for thorough
pre-clinical testing in predictive animal models. Likewise, the
development of pan-genotypic prophylactic or therapeutic vac-
cines instrumental in containing the HCV epidemic in resource-
poor communities would be greatly accelerated by a tractable
animal model.
Chimpanzees are the only available immunocompetent in vivo
experimental system, but their use is limited by ethical concerns,
restricted availability and prohibitively high costs. Undoubtedly,
more tangible animal models are needed not only to prioritize
clinical development of vaccine and drug candidates, but also to
gain deeper insights into virus–host biology. The study of HCV in
conventional cell culture systems, i.e. human hepatoma cells, may
not accurately reﬂect host responses to infection. With the advent
of more sensitive detection methods for viral infection and
improved technical ability to culture primary hepatocytes it is
now possible to dissect HCV infection in a physiological-relevant
environment (Jones et al., 2010a; Ploss et al., 2010). However,
even in the most advanced tissue culture platforms, including
micropatterned primary hepatocyte co-cultures (MPCCs; Jones
et al., 2010a; Khetani and Bhatia, 2008; Ploss et al., 2010), cultures
of human fetal hepatocytes (Andrus et al., 2011; Marukian et al.,
2011), or hepatocyte-like cells derived from induced pluripotent-
stem cells (iPSCs; Roelandt et al., 2012; Schwartz et al., 2012; Wu
et al., 2012), important features of liver biology as yet cannot be
adequately recapitulated. Within the liver, numerous cell types,
including hepatocytes and various non-parenchymal cell subsets
(i.e. liver sinusoidal endothelial cells, stellate cells, and oval cells),
are arranged in an intricate three-dimensional architecture.
Nutrient and oxygen gradients within the liver result in a
compartmentalization of the liver, referred to as zonation, affect-
ing metabolism, detoxiﬁcation and response to injury. Whether
those speciﬁc microenvironments impact HCV infection is not
understood and may only be adequately modeled within the
three-dimensional context of the liver. Furthermore, a tractable
animal model may be suitable to decipher mechanisms of viralTable 1
HCV susceptibility of selected species.
Human Great ape(s) (chimpanzee)
HCV susceptibility yes yes
Entry yes yes
Replication yes yes
Assembly yes yespersistence and pathogenesis and assess disease states and co-
morbidities, such as HIV, alcohol or nutritionally exacerbated viral
hepatitis, or extrahepatic manifestations associated with HCV
infection.The chimpanzee model
The only hosts known to be naturally permissive to HCV
infection are humans and chimpanzees (Table 1). The basis for
this limited species tropism is incompletely understood and the
topic of this review. The chimpanzee model played an instru-
mental role in early characterization of non-A, non-B hepatitis
(Houghton, 2009) which ultimately led to the discovery of HCV as
the etiologic agent for the classically deﬁned non-A non-B
hepatitis by Michael Houghton and his team in 1989 (Choo
et al., 1989). Subsequently, many important discoveries were
facilitated by their use; for example it was ﬁrst demonstrated in
chimpanzees that in vitro transcribed RNA from a HCV cDNA clone
was infectious (Kolykhalov et al., 1997). Furthermore, experimen-
tal infection of chimpanzees with HCV helped to deﬁne the nature
of protective immunity (Farci et al., 1992; Prince et al., 1992) and
to demonstrate the signiﬁcance of cellular subsets, most strin-
gently the role of CD4 and CD8 T cells in controlling chronic HCV
infection (Grakoui et al., 2003; Shoukry et al., 2003). Chimpanzees
remain the only fully immunocompetent animal model for HCV
infection and consequently, have and continue to play an impor-
tant role in evaluating the preclinical efﬁcacy of vaccine candi-
dates (reviewed in Houghton, 2011). Precedence for the efﬁcacy
of new treatment modalities, such as the IFN-free control of HCV
infection with DAAs (Olsen et al., 2011) or interference with the
liver speciﬁc microRNA (miR) 122 (Lanford et al., 2010) was ﬁrst
shown in chimpanzees. Despite their utility, the use of large apes
in biomedical research has raised ethical concerns, which culmi-
nated in the ban of experiments conducted in chimpanzees in
many countries. An NIH moratorium on ‘non-essential’ chimpanzee
research (NIH, 2011) is likely to constrain HCV research in the
future and has made the need for alternative animal models even
more pressing.HCV infection in other primate species
The natural host reservoir of HCV remains poorly deﬁned.
While chimpanzees can be experimentally infected with HCV, the
prevalence in chimpanzees or other great apes, gorillas and
orangutans in the wild is not known. In search of alternative,
more readily accessible experimental models for HCV numerous
species have been tested for their susceptibility to HCV. Wood-
chucks, old- and new-world monkeys, including Cynomolgus,
Rhesus, Japanese, Green monkeys, Doguera (Abe et al., 1993),
Chacma Baboons (Sithebe et al., 2002), Cottontop tamarins
(Garson et al., 1997) and marmosets appear to be mostly resistantTree shrew Monkeys (rhesus macaque) Mice
yes yes no
yes yes no
yes no no
yes ? yes
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which are distantly related to primates (Schmitz et al., 2000; Xu
et al., 2012) appear to support HCV infection to some level (Xie
et al., 1998; Xu et al., 2007) (Table 1) and were recently shown to
develop signs of severe liver disease, including steatosis, ﬁbrosis
and cirrhosis (Amako et al., 2010). While these data are encoura-
ging additional studies with larger cohorts of this outbred and
thus, genetically heterogeneous species, are needed to deﬁne
more clearly the natural course of HCV infection in tree shrews.Surrogate virus systems
Genetically related viruses, which replicate more readily in
non-human species have been considered as potential surrogates
for the study of HCV in vivo. Most prominently, GB viruses (GBV),
named after the surgeon George Baber (GB) who presented with
acute viral hepatitis in the 1960s (Deinhardt et al., 1967),
speciﬁcally GBV-B, can be transmitted to new world monkeys
(Bukh et al., 2001; Karayiannis et al., 1989; Lanford et al., 2003;
Schaluder et al., 1995; Simons et al., 1995). GBV-B and HCV both
belong to the Flaviviridae family but share only approximately
28% amino acid identity within their polyprotein, which con-
strains the utility of this model for testing of drugs speciﬁc to HCV
or vaccine candidates formulated with HCV speciﬁc antigens.
Another caveat is the different course of GBV-B infection in
tamarins and marmoset, which results in acute hepatitis but –
in contrast to HCV – does not establish chronicity. More recently,
other viruses that are genetically more related to HCV than GBV-B
have been detected in other species. Non-primate hepaci-virus
(NPHV), also known as canine hepacivirus (CHV) has been
identiﬁed in dogs (Kapoor et al., 2011) and horses (Burbelo
et al., 2012). Intriguingly, CHV/NPHV appears to have a broader
tissue tropism in these species but has yet to be shown to cause
hepatitis. Comparative analysis of CHV/NPHV and HCV may help
to shed light on potentially common viral and host factors
determining viral host and tissue tropism.Murine xenotransplantation models
Since HCV does not readily replicate in non-human species
conceptually the most straightforward strategy would be to
introduce the relevant tissue compartment – a human liver –
into mice. To this end various approaches have been taken
including transplantation of human liver pieces under the kidney
capsule (Ilan et al., 2002), engraftment of ‘‘human ectopic artiﬁcial
livers’’ (HEALs) in the peritoneal cavity (Chen et al., 2011) or actual
expansion of human hepatocytes within the liver parenchyma
(reviewed in de Jong et al. (2010) and Meuleman and Leroux-
Roels (2008b) of immunocompromised mice. For the latter
approach, suitable xenorecipients combine two features; immu-
nodeﬁciency to prevent graft rejection and liver injury to provide a
growth stimulus for the normally quiescent hepatocytes as well as
yield the transplanted human cells a competitive growth advan-
tage over endogenous murine cells. The best-characterized liver
injury mouse strains are urokinase-type plasminogen activator
(uPA) transgenic mice (Heckel et al., 1990) and mice deﬁcient in
fumaryl acetoacetate hydrolase (FAH; Grompe et al., 1993). When
crossed to an immunodeﬁcient background the livers of either line
can be highly repopulated with human hepatocytes, rendering the
human liver chimeric mice susceptible to HCV infection (Bissig
et al., 2010; Mercer et al., 2001; Meuleman et al., 2005). Such
humanized mice have been invaluable to study basic aspects of
HCV biology within the three-dimensional context of the liver and
assessing preclinically the efﬁcacy of antiviral compounds andbiologics (reviewed in Meuleman and Leroux-Roels (2008a)).
However, presumably due to their immunocompromised status
HCV infected human liver chimeric mice generally do not exhibit
signs of progressive liver disease, a process that is thought to be
immune-mediated in humans. To overcome this caveat, engrafting
components of a human immune system alongside human hepa-
tocytes in a single recipient has been proposed (Legrand et al.,
2009). Proof-of-concept for this strategy was provided in a recent
study showing that mice co-injected with a mixture of human
hematopoietic stem cells, fetal hepatoblasts and other non-
parenchymal cells could be infected with HCV and develop signs
of liver ﬁbrosis (Washburn et al., 2011). While intriguing, human
immune responses are generally weak in these reconstituted mice
and additional modiﬁcations will be needed to improve both
cellular complexity and functionality of the engrafted human
immune system (reviewed in Shultz et al. (2007) and Willinger
et al. (2011)). The utility of these xenotransplantation models is
hampered by low through-put, intricate logistics, high costs and
technical difﬁculties in their production but also the inherent
donor-to-donor variability and differences in the human chimerism
between animals.Blocks in the HCV lifecycle in non-permissive species
An inbred mouse model for HCV would overcome the technical
difﬁculties of the xenotransplantation model. Mice with inheri-
table susceptibility to HCV could be produced fairly easily in large
quantities, would be amendable to genetic manipulations on
deﬁned genetic backgrounds and viral infection could be analyzed
with a vast amount of existing tools and reagents. The challenge is
to elucidate and overcome restrictions for HCV to complete its
lifecycle in mouse cells and mice (Fig. 1). In recent years progress
has been made in explaining aspects of the restricted host range
of HCV. In the following sections, we will highlight barriers in the
HCV lifecycle in non-permissive species, focusing on mice, and
discuss putative strategies to overcome them.
HCV entry
A large number of cellular factors has been implicated in
facilitating HCV entry into human cells. In a coordinated multi-
step process (Table 2, reviewed in Ploss and Evans (2012)) HCV,
complexed with host lipoproteins in so called lipo-viroparticles, is
thought to initially attach to glycosaminoglycans, then binds to
low-density lipoprotein receptor (LDLR), the scavenger receptor
class B type I (SCARB1; Scarselli et al., 2002) and the tetraspanin
CD81 (Pileri et al., 1998) on the hepatocyte surface, before
engaging the tight junction proteins, claudin-1 (CLDN1; Evans
et al., 2007) and occludin (OCLN; Liu et al., 2009; Ploss et al.,
2009), ultimately resulting in endocytotic uptake (Fig. 1). More
recently, the receptor tyrosine kinases epidermal growth factor
receptor (EGFR) and ephrin receptor A2 (EphA2; Lupberger et al.,
2011) and the cholesterol uptake receptor Niemann-Pick C1 like 1
(NPC1L1; Sainz et al., 2012) have been implicated in the viral
entry process by indirectly inﬂuencing the composition of mem-
brane microdomains.
The C-type lectins liver/lymph node-speciﬁc intercellular
adhesion molecule-3-grabbing integrin (L-SIGN, CD209L;
Cormier et al., 2004), which is expressed on liver sinusoidal
endothelial cells (LSECs) and the dendritic cell-speciﬁc intercel-
lular adhesion molecule-3-grabbing nonintegrin (DC-SIGN,
CD209), expressed by dendritic and Kupffer cells have been
shown to bind to HCV E2 (Gardner et al., 2003; Lozach et al.,
2003; Pohlmann et al., 2003). C-type lectins on sinusoidal cells
may be able to trap HCV in the liver, but it is not known whether
Fig. 1. Blocks in HCV species tropism. Mouse hepatocytes support HCV replication cycle incompletely. CLDN1, claudin1; EGFR, epidermal growth factor receptor; EphA2,
ephrin receptor A2; GAG, Glycosaminoglycans; LDLR, low-density lipoprotein receptor; NPC1L1, Niemann-Pick C1-Like 1; OCLN, occludin; SCARB1, scavenger receptor
class B member 1. (þ) supported, () blocked step in the HCV lifecycle in murine cells.
Table 2
Expression of HCV entry factor candidates in human and mice.
Gene Most abundant tissue expression Liver expression Sequence
identity
(%)
Reference
Human Mouse Human Mouse Human Mouse
CD81 cd81 Ubiquitous Ubiquitous þ þ 96.6 Pileri et al. (1998)
OCLN ocln All tight junctions All tight junctions þ þ 94.5 Ploss et al. (2009)
CLDN1 cldn1 Skin, liver Skin, liver þ þ 97.2 Evans et al. (2007)
SCARB1 scarb1 Liver, adrenal tissue,placenta Liver, adrenal tissue, ovary þ þ 88.6 Scarselli et al. (2002)
LDLR ldlr Liver, intestine Liver, intestine þ þ 86.7 Molina et al. (2007) and Agnello
et al. (1999)
NPC1L1 npc1l1 Small intestine, liver,
stomach
Small intestine þ  84.7 Sainz et al. (2012)
EGFR egfr Ubiquitous, except central
nervous tissue
Ubiquitous, except central
nervous tissue
þ þ 95.1 Lupberger et al. (2011)
EphA2 epha2 Epithelial endothelial cells Epithelial endothelial cells þ þ 95.8 Lupberger et al. (2011)
PCDHB5 pcdhb5 Connective tissue Connective tissue   82.0 Wong-Staal et al. (2008)
TfR1 tfr1 Immature erythroid cells,
placenta, liver
Immature erythroid cells,
placenta, liver
þ þ 87.0 Danyelle et al. (2008)
CLDN6 cldn6 Embryonic tissue, pituitary
gland, ovary
Embryonic tissue, pituitary
gland, ovary
  95.0 Zheng et al. (2007) and Meertens
et al. (2008)
CLDN9 cldn9 Pituitary gland,
lung,intestine
Pituitary gland,
lung,intestine
  99.1 Zheng et al. (2007) and Meertens
et al. (2008)
CD209 cd209 Dendritic cells Dendritic cells   52.3 Gardner et al. (2003)
CD209L/DC-
SIGNR
signr1
(signr2–4)
Lymph node, liver,placenta Lymph node, spleen,
pancreas
þ þ 54.5 Gardner et al. (2003)
L. Sandmann, A. Ploss / Virology 435 (2013) 70–80 73this can lead to productive infection of hepatocytes in trans or
whether sequestered HCV is subjected to lysosomal degradation.
Other molecules such as CLDN6, CLDN9 (Meertens et al., 2008;
Zheng et al., 2007), transferrin receptor (TfR; Martin and
Uprichard, 2010) and protocadherin 5 (PCDHB5; Wong-Staal
et al., 2008) have been proposed to be involved in inﬂuencing HCV
entry. However, CLDN6, CLDN9 nor PCDHB5 are expressed at
appreciable levels in the liver (Table 2). Thus, strong experimental
evidence supporting their suggested relevance for viral entry and
independent conﬁrmation of these results still remain pending.In contrast to human hepatocytes, murine cells do not support
HCV entry thereby creating a ﬁrst and important barrier for a
broader host tropism of the virus. In an attempt to deﬁne the
determinants restricting HCV entry into non-human cells a cDNA
complementation screen was conducted in mouse cells ectopi-
cally expressing human CD81, SCARB1 and CLDN1 (Ploss et al.,
2009). Human OCLN was identiﬁed as the missing factor needed
to facilitate viral entry into human and mouse cells. While CD81,
SCARB1, CLDN1 and OCLN are all required, only CD81 and OCLN
need to be of human origin to promote viral entry into mouse
L. Sandmann, A. Ploss / Virology 435 (2013) 70–8074cells (Ploss et al., 2009). These observations are in line with
previous reports demonstrating that in contrast to CD81 of
various non-human primate species, mouse CD81 does not sup-
port HCV pseudoparticle entry into human HepG2 hepatoma
cells, which lack endogenous expression of CD81 (Flint et al.,
2006). Similarly, in human cells lacking endogenous OCLN expres-
sion, primate sequences function equivalently to human OCLN,
whereas canine, hamster, mouse and rat OCLN had intermediate
to low activities, and guinea pig OCLN was completely nonfunc-
tional (Michta et al., 2010). For both CD81 and OCLN, differences
in the second extracellular loops are in part responsible for this
apparent functional activity. In contrast, the residues (I32 and
E48) within the ﬁrst extracellular loop of CLDN1 required for HCV
entry (Evans et al., 2007) are conserved between mice and man.
Thus, it is not surprising that mouse CLDN1 supports HCV uptake.
Originally, it was shown that human but not mouse SCARB1 can
bind to soluble HCV E2 (Scarselli et al., 2002). Nonetheless, in
both in vitro (Ploss et al., 2009) and in vivo (Dorner et al., 2011)
infection assays mouse and human SCARB1 were equally func-
tional. These apparently conﬂicting data are likely attributable to
the read-out system and highlight that HCV E2 binding may not
be the most reliable proxy for functional entry assays. To date any
differences in the susceptibility of cells of non-human origin to
HCV entry are largely accounted for by differences in critical
positions within respective orthologues of CD81, SCARB1, CLDN1
and OCLN or their limited or absent expression.
Genetically humanized mice for HCV entry
The observation that CD81 and OCLN comprise the minimal
set of human factors required to render mouse cells permissive to
HCV entry in vitro provided the blue print for engineering a mouse
that at least supports viral uptake in vivo. Genetically humanized
mice have been successfully constructed by expression of recep-
tors and/or coreceptors in mice for other human pathogens, such
as poliovirus (hCD155; Racaniello and Ren, 1994), measles virus
(hCD46/CD150; Sellin and Horvat, 2009), human coronavirus
(hCD13; Lassnig et al., 2005), human immunodeﬁciency virus
(hCD4/CCR5/CXCR4; Klotman and Notkins, 1996) and Listeria
monocytogenes (Lecuit et al., 2001). Earlier attempts to render
mice susceptible to HCV infection by transgenic expression of
CD81 were not successful (Masciopinto et al., 2002). Expression of
human CD81 in a wide variety of tissues increased the binding of
recombinant E2 to liver, thymocytes and splenic lymphocytes in
comparison to non-transgenic controls, but due to the lack of
human OCLN human CD81-transgenic mice were resistant to HCV
infection.
Recently, it was demonstrated that adenoviral delivery of
human CD81 and OCLN is sufﬁcient to allow HCV infection of
fully-immunocompetent inbred mice (Dorner et al., 2011). Using
intergenotypic virus chimeras expressing CRE recombinase to
activate a cellular reporter, in vivo uptake of diverse HCV
genotypes could be conveniently quantiﬁed by bioluminescent
imaging. Utilizing blocking antibodies speciﬁc to CD81 or the viral
envelope protein E2, expression of entry factor mutants and mice
with a targeted disruption of the SCARB1 gene validated uptake of
HCV into murine hepatocytes in an HCV glycoprotein-mediated
fashion. Furthermore, it established a precedent for applying
mouse genetics to dissect the viral entry process, in addition to
validating the role of SCARB1 for HCV uptake in vivo for the ﬁrst
time. Beyond studying HCV entry, this model can be employed to
evaluated passive and active immunization strategies (Dorner
et al., 2011, in press; Giang et al., 2012).
The transient adenoviral delivery approach is high-throughput
and allows rapid evaluation of mutant genes. However, in order to
accurately reproduce the complex process of HCV entry in vivo, itwill be important to achieve native expression patterns of the
human HCV entry factor orthologues by using transgenic and/or
knock-in approaches. Recently, transgenic mice expressing
human CD81, SCARB1, CLDN1 and OCLN were generated, but
did not appear to be permissive to HCV infection in vivo (Hikosaka
et al., 2011). This apparent discrepancy between transient ade-
noviral and stable transgenic expression approaches can be in
part explained by the lower level of entry factor expression in the
transgenic mice and the requirement for a very sensitive reporter
system to quantify viral entry (Dorner et al., 2011).
Adaptation of HCV to infection of mouse cells
As an alternative to this host adaptation approach to overcome
species barriers it may be possible to adapt HCV to usage of entry
factor orthologs from other species. Using an unbiased selection
approach, a laboratory strain of HCV was adapted to utilize mouse
CD81 (Bitzegeio et al., 2010). Taking advantage of the high
mutational plasticity of HCV, three adaptive mutations in the
viral glycoproteins E1 and E2 were identiﬁed that allowed the
virus to enter cells expressing human SCARB1, CLDN1, OCLN and
mouse CD81. Interestingly, the resulting murine-tropic (mt) HCV
was also capable of efﬁciently utilizing mouse OCLN and had a
lower dependency on SCARB1. Whether mtHCV is capable of
infecting mouse hepatocytes in vitro or in vivo has yet to be
shown. Clearly, this study provides an important proof-of-concept
for the validity of the viral adaptation approach but also raises a
few potential caveats. The adaptive mutations within the viral
envelope appear to have resulted in conformational changes.
Consequently, it remains to be tested whether mtHCV faithfully
recapitulates viral entry and raises concerns of whether the
neutralizing capacity of antibodies or human speciﬁc therapeutics
to block HCV entry can be adequately tested.
The contribution of other host factors implicated in viral entry
to the species tropism of HCV is not well understood. Most human
and murine orthologues share a high degree of amino acid
sequence similarity (Table 2) but, as discussed above, differences
in individual residues can drastically affect viral uptake efﬁciency.
The exact roles of EGF receptor and ephrin receptor A2, which are
both expressed in mouse and human hepatocytes, in this process
are incompletely deﬁned. Both receptor tyrosine kinases (RTKs)
appear to mediate entry by regulating CD81–CLDN1 co-receptor
associations and viral glycoprotein-dependent membrane fusion
(Lupberger et al., 2011). Recently, it was shown that EGFR
activation is dependent on interactions between HCV and CD81
but not CLDN1 (Diao et al., 2012). Although, it is conceivable that
expression of human EGFR and/or ephrin receptor A2 could increase
HCV entry efﬁciency in vivo their murine orthologues appear to exert
sufﬁcient functionality in genetically humanized mice.
Interestingly, although NPC1L1 has been shown to play a role
in the viral entry in human cells in vitro and in vivo (Sainz et al.,
2012) it appears to be dispensable for entry into mouse cells. In
contrast to humans, the murine ortholog of NPC1L1 has approxi-
mately 85% sequence similarity to the human protein and is
abundantly expressed in the gut but not in the liver (Altmann
et al., 2004). Nonetheless, HCV is still capable of entering into
hepatocytes of mice modiﬁed to express a combination of human
CD81 and OCLN (Dorner et al., 2011) suggesting some level of
redundancy for NPC1L1 in this process. It is conceivable that HCV
entry would be affected, perhaps becoming more efﬁcient, if
NPC1L1 along with human CD81 and OCLN was ectopically
co-expressed in the liver, which remains to be experimentally
tested. It was recently demonstrated that hepatic overexpression
of human NPC1L1 in transgenic mice (Temel et al., 2007) or via
adenoviral delivery modulates cellular and plasma lipid metabo-
lism (Kurano et al., 2012). Altered cellular lipid proﬁles can
L. Sandmann, A. Ploss / Virology 435 (2013) 70–80 75arguably affect the composition of membrane microdomains and
consequently, the trafﬁcking of membrane proteins including
HCV entry factors.
Fusion, uncoating and initial HCV RNA translation
Following receptor mediated endocytosis the viral membrane
has to fuse with the endosome to eventually release the HCV RNA
genome from the nucleocapsid into the cytoplasm. It has been
known that viral RNA translation occurs in vivo, when the RNA is
directly introduced into mouse hepatocytes, e.g. by hydrodynamic
delivery (McCaffrey et al., 2002). This suggests that the HCV
internal ribosome entry site (IRES) within the 50 untranslated
region is functional in mouse cells. Recently, a genetically huma-
nized mouse model was constructed utilizing cell culture pro-
duced recombinant hepatitis C virus to activate a cellular encoded
reporter (Dorner et al., 2011, in press). In this model HCV is taken
up into murine hepatocytes in a viral glycoprotein-dependent
fashion providing further evidence that fusion and uncoating
work efﬁciently in this background.
HCV RNA replication
The advent of HCV replicons, i.e. subgenomic or full-length
genomes containing a dominant selectable marker such as neo-
mycin amino transferase (Blight et al., 2000; Lohmann et al.,
1999), allowed for assessing whether HCV is capable of replicat-
ing in non-human cells. Indeed, when these replicons were
introduced into mouse hepatoma cell lines and embryonic ﬁbro-
blasts, cell clones harboring replicating HCV RNA could be
identiﬁed at very low frequency (Uprichard et al., 2006; Zhu
et al., 2003). These data suggest that all necessary host factors are
present in mouse cells and sufﬁciently similar to support HCV
RNA replication. However, it is conceivable that the viral RNA
replication machinery cooperates more robustly with essential
human host factors than their murine counterparts. Targeted and
genome wide loss of function screens led to the discovery of
numerous cellular factors putatively promoting or restricting HCV
replication in human cells (Berger et al., 2009; Borawski et al.,
2009; Coller et al., 2009; Jones et al., 2010b; Li et al., 2009; Ng
et al., 2007; Randall et al., 2007; Reiss et al., 2011; Supekova et al.,
2008; Tai et al., 2009; Trotard et al., 2009; Vaillancourt et al.,
2009). Unfortunately, independent studies are often minimally
overlapping and the relevance of many of these interactions to
HCV biology remains to be demonstrated. Strong experimental
evidence has been provided for the critical role of cyclophilin A
(CypA) in RNA replication and virion assembly (Kaul et al., 2009;
Yang et al., 2008). Another essential co-factor for RNA replication
independently identiﬁed by several groups (Berger et al., 2009;
Borawski et al., 2009; Reiss et al., 2011; Tai et al., 2009; Trotard
et al., 2009), is phosphatidylinositol 4 kinase III (PI4KIII). PI4KIII is
recruited to the membranous web via interaction with NS5A. The
human and murine orthologues of CypA and PI4KIII share a high
degree of sequence similarity at 98.2 and 98.6%, respectively. It is
yet to be shown whether ectopic expression of human CypA and
PI4KIII augments HCV RNA replication in mouse cells. Likewise,
there is little evidence for the accumulation of adaptive mutations
boosting viral RNA replication in mouse cells by fostering more
efﬁcient interactions with mouse orthologues of host factors.
Cellular microRNAs can drastically inﬂuence virus replication
and pathogenesis (Gottwein and Cullen, 2008). A liver speciﬁc
microRNA, miR-122, was shown to be critical for efﬁcient HCV
RNA replication (Jopling et al., 2005). miR-122 is derived from a
liver-speciﬁc noncoding polyadenylated RNA transcribed from the
gene hcr and interacts with two sites in the viral 50 non-translated
region (NTR) (Jopling et al., 2008, 2005). Those interactionspresumably protect the 50 terminal viral sequences from nucleolytic
degradation or from inducing innate immune responses to the RNA
terminus (Machlin et al., 2011), resulting in greater viral RNA
abundance in both infected cultured cells and in the liver of infected
chimpanzees (Lanford et al., 2010). The exact sequence of miR-122 is
highly conserved in vertebrate species; comparatively, mouse miR-
122 is sequence-wise identical and with 50,000 copies per hepato-
cytes similarly expressed as the human counterpart (Chang et al.,
2004). Consequently, miR-122 is not likely to contribute to the
restricted host tropism in non-permissive species.
It is possible that cell-intrinsic, species-speciﬁc restriction
factors, similar to those that control retroviral infection, such as
Fv1, TRIM5 or APOBEC3 cytidine deaminases (reviewed in
Bieniasz (2004)), interfere with HCV RNA replication in murine
cells. However, heterokaryons of mouse and human cells capable
of supporting the HCV lifecycle suggest that dominant negative
inhibitors of HCV replication do not exist (Frentzen et al., 2011).
Antiviral cellular defenses limiting HCV RNA replication
Differences in the magnitude, nature and kinetics of an
antiviral response between hosts are known to restrict tropism
of certain viruses, such as myxoma virus, which is only permissive
in mouse cells that have impaired IFN responses (Wang et al.,
2004). The interferon system also plays a pivotal role in limiting
HCV both under physiological conditions and when triggered
during therapeutic intervention. Hundreds of IFN stimulated
genes (ISGs) are induced in the liver during HCV infection
(reviewed in Schoggins and Rice (2011)) and ISG products can
potently inhibit HCV infection (Schoggins et al., 2011; Fig. 2).
Pattern recognition receptors (PRRs) such as Toll-like receptors
(TLRs)-3 and 7 in endosomes as well as a family of RIG-I like
receptors (RLRs), including the retinoic-acid-inducible gene I
(RIG-I) and the melanoma-differentiation-associated gene 5
(MDA5) sense the presence of viral RNAs. Subsequently, host
antiviral responses are activated resulting in the production of
cytokines, such as type I and III interferons (Yoneyama et al.,
2004). When IFN signaling is blunted, HCV replicates more
efﬁciently in both human hepatoma cells (Blight et al., 2002)
and primary human hepatocytes (Andrus et al., 2011; Marukian
et al., 2011). Similarly, in mouse embryonic ﬁbroblasts with
targeted disruptions in protein kinase R (PKR; Chang et al.,
2006) or interferon regulatory factor 3 (IRF3; Lin et al., 2010)
RNA replication is enhanced. Whether disruption of these or other
innate signaling pathways are sufﬁcient to render mice expres-
sing human HCV entry factors permissive to HCV infections has
yet to be shown.
HCV has devised mechanisms to counteract innate defenses
but those may not work equally efﬁcient in cells from different
species. For example, NS3–4A serine protease is not only essential
for processing of the HCV polyprotein but has been shown to
cleave the mitochondrial associated antiviral signaling protein
(MAVS; Meylan et al., 2005), the T-cell protein tyrosine phospha-
tase (TC-PTP; Brenndorfer et al., 2009) and TIR domain-containing
adapter inducing IFN (TRIF; Li et al., 2005) thereby modulating
antiviral signaling. The cleavage motifs of MAVS and TRIF are
partially conserved between mice and man/chimpanzees (Fig. 2)
and it remains to be demonstrated whether these antiviral
evasion strategies are functional in murine cells. Contrarily, MAVS
from certain new world monkey species, including rhesus maca-
ques and baboons, both of which are resistant to HCV infection, is
functional for interferon signaling even in the presence of hetero-
logously expressed NS3/4A protease in human epithelial cells.
Thus, escape from HCV antagonism of innate immune sensing
may explain at least part of HCV species restriction (Patel et al.,
2012). Furthermore, other aspects of HCVs antiviral evasion
Fig. 2. Innate immune response to HCV infection. Ch; chimpanzee, dsRNA, double-stranded RNA; ER, endoplasmatic reticulum; hu, human; IFN, interferon; IFNAR,
interferon-alpha receptor; IL, interleukin; IRF, interferon regulatory factor; JAK, Janus kinase; ms, mouse; MAVS, mitochondrial associated antiviral signaling protein;
MDA5, melanoma-differentiation-associated gene 5; PKR, protein kinase R; rh, rhesus macaque; RIG-I, retinoic-acid-inducible gene I; ssRNA, single-stranded RNA; STAT1,
signal transducer and activator of transcription protein-1; STAT2, signal transducer and activator of transcription protein-2; STING, stimulator of interferon genes; TLR,
toll-like receptor; TRIF, TIR-domain-containing adapter-inducing interferon; TYK, tyrosine kinase. Inlet: sequence alignment of the NS3–4a cleavage motif within MAVS
from different permissive and non-permissive species.
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NS4B was shown to inhibit RLR-mediated IFN signaling through
association with the stimulator of interferon genes (STING; Nitta
et al., in press). Similarly, overexpression data suggests that the
HCV core protein interferes with IFN signaling downstream of the
IFN receptor, presumably through direct interaction with STAT1,
leading to reduced phospho-STAT1. The protein sequences of
mouse and human STAT1 are highly conserved (490% sequence
identity), mouse and human STING are only ca. 60% identical (ca.
80% similar) which may result in a weaker interaction of NS4B
with the murine orthologue and consequently, more exacerbated
RLR signaling.
HCV assembly, egress and release from mouse cells
The development of the infectious cell culture system, which
recapitulates all parts of the viral lifecycle paved the way to study
HCV assembly, egress and release. Increasing evidence points to a
connection between the viral lifecycle and the biogenesis of host
very low-density lipoproteins (VLDL) (Huang et al., 2007; Merz et al.,
2011; Ye, 2007). Very low-density viral particles can be detected in
sera from HCVþ patients using antibodies targeting lipoprotein-
associated proteins, notably apolipoproteins (apo) B and E (Nielsen
et al., 2006). The role of speciﬁc apolipoproteins in virion assembly is
incompletely understood. Loss of function experiments have pointed
towards apoA1 (Mancone et al., 2011), apoB (Huang et al., 2007),
and apoE (reviewed in Bartenschlager et al. (2011)) as potential
players in this process.
While human cells with a functional VLDL pathway are
capable of producing infectious HCV it was unclear whether other
species would also support late stages of the HCV lifecycle.
To investigate this process mouse Hep56.1D cells harboring a
subgenomic HCV replicon were transcomplemented with HCV
core, E1, E2, p7 and NS2 proteins but only marginal amounts of
infectious HCV were released (Long et al., 2011). A comparativetranscriptome analysis between naı¨ve mouse cells and those
containing HCV replicons hinted that low levels of apoE in the
replicon-containing cells might limit HCV assembly. Indeed,
complementation with human or mouse apoE was sufﬁcient to
rescue infectious HCV production from these cells, yielding
infectious titers similar to those observed in the widely used
human hepatoma cell line, Huh-7.5. These data conﬁrm the
critical importance of apoE in HCV assembly and provide evidence
that mouse cells can support the late stages of HCV lifecycle, if
critical components of the VLDL pathway are present. However, it
remains unclear whether HCV can assemble in more physiologi-
cally relevant systems and importantly if mice are capable of
producing infectious particles in vivo.Conclusions and future perspectives
Substantial progress has been made in our understanding of
the HCV lifecycle which is being translated into improved
therapies. Experimental systems devised to study HCV in cell
culture have enabled comparative studies to elucidate the bar-
riers that restrict HCV infection to humans and chimpanzees.
While murine cells can be engineered to express the human
orthologs of the entry molecules CD81 and occludin to allow
entry, viral RNA replication is still low in these cells. This is at
least in part due to varying antiviral defenses. Murine cells with
an intact VLDL pathway can produce infectious virions. Taken
together these observations raise the hope that an inbred mouse
model for HCV infection can be achieved. Recapitulating the
entire viral lifecycle in a mouse would certainly be of great
importance but it remains to be seen whether such a model
would also mimic clinical relevant disease aspects. In humans
pathogenesis in the context of chronic HCV infection is thought
to be driven by persistent liver inﬂammation ultimately resulting
in ﬁbrosis, cirrhosis and liver cancer. Thus, establishing HCV
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likely necessary to model adequately HCV pathogenesis. Studies
characterizing chronicity in humanized mice engrafted with both
human hepatocytes and components of a human immune system
(Washburn et al., 2011) as well as long-term follow up studies in
tree shrews (Amako et al., 2010) hint that it may become possible
to dissect liver disease progression in small animal models. The
course of HCV infection has been studied in great detail in
chimpanzees and by and large mirrors adequately acute and
chronic HCV infection in humans. Whether HCV infection in other
species such as inbred mice will follow a similar clinical course is
unclear. However, even if HCV infections were to cause e.g.
mostly acute hepatitis in mice inheritable traits rendering ani-
mals permissive to HCV could be combined with genetic back-
grounds that are more prone for chronicity and liver disease
progression. Different approaches, including both viral and host
adaptations are likely needed to construct a selection of HCV
permissive animal models, which in combination may be suitable
to replace the chimpanzee. A cost-effective animal model that is
amendable to genetic manipulations and can be reproducibly
produced at higher throughput would undoubtedly lend itself to
address currently intractable problems in HCV research.Acknowledgments
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